Quick Answer
Allogene Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Allogene Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$22.0K -76.8% |
$95.0K -39.1% |
$156.0K -99.9% |
$114.09M | $0.00 |
| Revenue (ASC 606) | $0.00 -100.0% |
$22.0K -76.8% |
$95.0K -39.1% |
$156.0K -99.9% |
$114.09M | $0.00 |
| Net Income | -$190.89M +25.9% |
-$257.59M +21.3% |
-$327.26M +3.9% |
-$340.41M -87.0% |
-$182.05M +27.2% |
-$250.22M -35.6% |
| Diluted EPS | -$0.87 +34.1% |
-$1.32 +36.8% |
-$2.09 +12.2% |
-$2.38 -77.6% |
-$1.34 +35.6% |
-$2.08 -13.7% |
| Total Assets | $415.90M -24.2% |
$548.71M -26.9% |
$750.13M -23.3% |
$978.09M -5.8% |
$1.04B -15.4% |
$1.23B +71.1% |
| Cash and Equivalents | $51.69M -31.3% |
$75.22M -31.6% |
$109.93M +30.1% |
$84.51M -51.2% |
$173.31M -5.5% |
$183.35M +4.7% |
| Stockholders Equity | $292.54M -30.7% |
$422.18M -28.7% |
$592.01M -31.6% |
$865.27M -6.5% |
$925.20M -8.7% |
$1.01B +61.1% |
| R&D Expense | $150.15M -21.9% |
$192.30M -20.8% |
$242.91M -5.3% |
$256.39M +16.4% |
$220.18M +14.1% |
$192.99M +33.5% |
| Operating Income | -$209.31M +23.4% |
-$273.20M +16.6% |
-$327.74M +2.3% |
-$335.54M -86.2% |
-$180.19M +30.2% |
-$258.24M -27.8% |
| Shares Outstanding | 229.41M +8.1% |
212.21M +45.6% |
145.74M +1.5% |
143.57M +0.7% |
142.62M +1.5% |
140.47M +13.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$41.40M | +37.5% | +18.7% |
| Diluted EPS | September 30, 2025 | -$0.19 | +40.6% | +17.4% |
| Total Assets | September 30, 2025 | $439.77M | -25.4% | -6.5% |
| Cash and Equivalents | September 30, 2025 | $37.81M | -26.2% | -27.7% |
| Stockholders Equity | September 30, 2025 | $315.33M | -32.0% | -8.5% |
| R&D Expense | September 30, 2025 | $31.16M | -30.3% | -22.4% |
| Operating Income | September 30, 2025 | -$44.90M | +37.4% | +21.0% |
| Shares Outstanding | September 30, 2025 | 223.16M | +6.5% | +1.4% |
- Allogene Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Allogene Therapeutics, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Allogene Therapeutics, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- Allogene Therapeutics, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Allogene Therapeutics, Inc. reported Net Income of -$190.89 million for fiscal year 2025.
- Allogene Therapeutics, Inc. showed an increase of +25.9% in Net Income compared to the prior fiscal year.
- Allogene Therapeutics, Inc. reported Diluted EPS of $0.87 per share (loss) for fiscal year 2025.
- Allogene Therapeutics, Inc. showed an increase of +34.1% in Diluted EPS compared to the prior fiscal year.
- Allogene Therapeutics, Inc. reported Total Assets of $415.90 million for fiscal year 2025.
- Allogene Therapeutics, Inc. showed a decrease of -24.2% in Total Assets compared to the prior fiscal year.
- Allogene Therapeutics, Inc. reported Cash and Equivalents of $51.69 million for fiscal year 2025.
- Allogene Therapeutics, Inc. showed a decrease of -31.3% in Cash and Equivalents compared to the prior fiscal year.
- Allogene Therapeutics, Inc. reported Stockholders Equity of $292.54 million for fiscal year 2025.
- Allogene Therapeutics, Inc. showed a decrease of -30.7% in Stockholders Equity compared to the prior fiscal year.
- Allogene Therapeutics, Inc. reported R&D Expense of $150.15 million for fiscal year 2025.
- Allogene Therapeutics, Inc. showed a decrease of -21.9% in R&D Expense compared to the prior fiscal year.
- Allogene Therapeutics, Inc. reported Operating Income of -$209.31 million for fiscal year 2025.
- Allogene Therapeutics, Inc. showed an increase of +23.4% in Operating Income compared to the prior fiscal year.
- Allogene Therapeutics, Inc. reported Shares Outstanding of 229.41 million shares for fiscal year 2025.
- Allogene Therapeutics, Inc. showed an increase of +8.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: